The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 101-59-87
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2024
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Nikitin P.V.

I.M. Sechenov First Moscow State Medical University

Belyaev A.Yu.

Burdenko Neurosurgical Center

Kobyakov G.L.

Burdenko Neurosurgical Center

Strunina Yu.V.

Burdenko Neurosurgical Center

Shugai S.V.

Burdenko Neurosurgical Center

Musina G.R.

Lomonosov Moscow State University

Usachev D.Yu.

Burdenko Neurosurgical Center

Timashev P.S.

Institute for Regenerative Medicine of the I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

NMDA receptors expression activity in anaplastic astrocytomas

Authors:

Nikitin P.V., Belyaev A.Yu., Kobyakov G.L., Strunina Yu.V., Shugai S.V., Musina G.R., Usachev D.Yu., Timashev P.S.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(1): 97‑102

DOI: 10.17116/jnevro202312301197

Views: 1344

Downloaded: 19

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Nikitin PV, Belyaev AYu, Kobyakov GL, et al. . NMDA receptors expression activity in anaplastic astrocytomas. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(1):97‑102. (In Russ.)
https://doi.org/10.17116/jnevro202312301197

Подписка 2025 (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Close metadata
Recommended articles:
Targeting NMDAR/AMPAR: a promising pharmacotherapeutic approach for depressive diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):22-30
Prognostic model for asse­ssing the human glioma cell mali­gnancy grade based on MDM2, MELK, SOX2, CDK4, DR5 and OCT4 gene expression. Burdenko's Journal of Neurosurgery. 2023;(6):43-51
Methodological approaches to asse­ssing inci­dence, survival, and mortality rates in breast cancer in the Russian Fede­ration. P.A. Herzen Journal of Onco­logy. 2024;(1):36-43
PET/CT with 11C-methionine in asse­ssment of brain glioma meta­bolism. Burdenko's Journal of Neurosurgery. 2024;(1):63-69
D2 and D3 lymph node dissection for colon cancer. Piro­gov Russian Journal of Surgery. 2024;(7):25-35
Liver transplantation program at the Burnasyan Fede­ral Biophysical Center: expe­rience in 500 procedures. Piro­gov Russian Journal of Surgery. 2024;(7):45-60
The significance of the perceived age for predicting of cardiovascular events mortality. Russian Journal of Preventive Medi­cine. 2024;(8):32-38

OBJECTIVE

To study the relationship of NMDA receptors expression activity with proliferative activity and genetic properties of anaplastic astrocytomas, as well as the survival of patients with this disease.

MATERIAL AND METHODS

To solve this problem, we compared the expression activity of the least studied NMDA receptors in the context under consideration, detected using immunofluorescent studies and polymerase chain reaction, with the results of histological and molecular studies, the proliferative activity of neoplasms, and the survival of patients.

RESULTS

The expression activity of NMDA receptors is higher in astrocytomas, grade 3, which do not carry mutations in IDH1 and IDH2 genes. In addition, the activity of NMDA receptors expression directly correlates with proliferative activity in the tumors. The activity of NMDA receptor expression has a significant impact on the prognosis of disease-free survival.

CONCLUSION

We have shown for the first time the significant role of NMDA receptors in the progression of diffuse astrocytomas, which can become the basis for creating new therapeutic and diagnostic tools.

Keywords:

diffuse gliomas
astrocytoma
glutamate
survival
NMDA receptors

Authors:

Nikitin P.V.

I.M. Sechenov First Moscow State Medical University

Belyaev A.Yu.

Burdenko Neurosurgical Center

Kobyakov G.L.

Burdenko Neurosurgical Center

Strunina Yu.V.

Burdenko Neurosurgical Center

Shugai S.V.

Burdenko Neurosurgical Center

Musina G.R.

Lomonosov Moscow State University

Usachev D.Yu.

Burdenko Neurosurgical Center

Timashev P.S.

Institute for Regenerative Medicine of the I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Received:

05.08.2022

Accepted:

17.08.2022

List of references:

  1. Izmailov TR, Kobyakov GL, Banov SM, et al. Association of Oncologists of Russia, Association of Neurosurgeons of Russia. Clinical guidelines «Primary tumors of the central nervous system». M., 2020;76. (In Russ.).
  2. Ostrom QT, Patil N, Cioffi G, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013—2017. Neuro Oncol. 2020;22(12 suppl 2):1-96.  https://doi.org/10.1093/neuonc/noaa200
  3. Ostrom QT, Gittleman H, Truitt G, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011—2015. Neuro Oncol. 2018;20(suppl 4):1-86.  https://doi.org/10.1093/neuonc/noy131
  4. Kobyakov GL, Absalyamova OV, Anikeeva OYu, et al. Practical guidelines for drug treatment of primary tumors of the central nervous system. Malignant Tumors. 2015;4:55-79. (In Russ.). https://doi.org/10.18027/2224-5057-2020-10-3s2-07
  5. Kobyakova EA, Usachev DYu, Absalyamova OV, et al. Criteria for assessing response to treatment in neuro-oncology (RANO): application in clinical trials and in routine practice. Pharmateka. 2021;28(11):21-33. (In Russ.). https://doi.org/10.18565/pharmateca.2021.11.21-33
  6. van den Bent MJ, Smits M, Kros JM, et al. Diffuse Infiltrating Oligodendroglioma and Astrocytoma. J Clin Oncol. 2017;35(21):2394-2401. https://doi.org/10.1200/JCO.2017.72.6737
  7. Caccese M, Padovan M, D’Avella D, et al. Anaplastic Astrocytoma: State of the art and future directions. Crit Rev Oncol Hematol. 2020;153:103062. https://doi.org/10.1016/j.critrevonc.2020.103062
  8. Venkatesh HS, Morishita W, Geraghty AC, et al. Electrical and synaptic integration of glioma into neural circuits. Nature. 2019;573(7775):539-545.  https://doi.org/10.1038/s41586-019-1563-y
  9. Venkataramani V, Tanev DI, Strahle C, et al. Glutamatergic synaptic input to glioma cells drives brain tumour progression. Nature. 2019;573(7775):532-538.  https://doi.org/10.1038/s41586-019-1564-x
  10. Smart TG, Paoletti P. Synaptic neurotransmitter-gated receptors. Cold Spring Harb Perspect Biol. 2012;4(3):a009662. https://doi.org/10.1101/cshperspect.a009662
  11. Lüscher C, Malenka RC. NMDA receptor-dependent long-term potentiation and long-term depression (LTP/LTD). Cold Spring Harb Perspect Biol. 2012;4(6):a005710. https://doi.org/10.1101/cshperspect.a005710
  12. Durante V, de Iure A, Loffredo V, et al. Alpha-synuclein targets GluN2A NMDA receptor subunit causing striatal synaptic dysfunction and visuospatial memory alteration. Brain. 2019;142(5):1365-1385. https://doi.org/10.1093/brain/awz065
  13. Nikitin VP, Kozyrev SA, Solntseva SV, et al. Protein synthesis inhibitor administration before a reminder caused recovery from amnesia induced by memory reconsolidation impairment with NMDA glutamate receptor antagonist. Brain Res Bull. 2021;171:44-55.  https://doi.org/10.1016/j.brainresbull.2021.03.008
  14. Ramaswamy P, Dalavaikodihalli NN, Prasad C, et al. Transcriptional modulation of calcium-permeable AMPA receptor subunits in glioblastoma by MEK-ERK1/2 inhibitors and their role in invasion. Cell Biol Int. 2020;44(3):830-837.  https://doi.org/10.1002/cbin.11279
  15. Pei Z, Lee KC, Khan A, et al. Pathway analysis of glutamate-mediated, calcium-related signaling in glioma progression. Biochem Pharmacol. 2020;176:113814. https://doi.org/10.1016/j.bcp.2020.113814
  16. Corsi L, Mescola A, Alessandrini A. Glutamate Receptors and Glioblastoma Multiforme: An Old «Route» for New Perspectives. Int J Mol Sci. 2019;20(7):1796. https://doi.org/10.3390/ijms20071796
  17. Venkataramani V, Tanev DI, Kuner T, et al. Synaptic input to brain tumors: clinical implications. Neuro Oncol. 2021;23(1):23-33.  https://doi.org/10.1093/neuonc/noaa158
  18. Gryder DS, Castaneda DC, Rogawski MA. Evidence for low GluR2 AMPA receptor subunit expression at synapses in the rat basolateral amygdala. J Neurochem. 2005;94(6):1728-1738. https://doi.org/10.1111/j.1471-4159.2005.03334.x
  19. Mayer J, Kirschstein T, Resch T, et al. Perampanel attenuates epileptiform phenotype in C6 glioma. Neurosci Lett. 2020;715:134629. https://doi.org/10.1016/j.neulet.2019.134629
  20. Mittelbronn M, Harter P, Warth A, et al. EGR-1 is regulated by N-methyl-D-aspartate-receptor stimulation and associated with patient survival in human high grade astrocytomas. Brain Pathol. 2009;19(2):195-204.  https://doi.org/10.1111/j.1750-3639.2008.00175.x
  21. Chen HS, Lipton SA. The chemical biology of clinically tolerated NMDA receptor antagonists. J Neurochem. 2006;97(6):1611-1626. https://doi.org/10.1111/j.1471-4159.2006.03991.x
  22. Limapichat W, Yu WY, Branigan E, et al. Key binding interactions for memantine in the NMDA receptor. ACS Chem Neurosci. 2013;4(2):255-260.  https://doi.org/10.1021/cn300180a
  23. Lavretsky H, Laird KT, Krause-Sorio B, et al. A Randomized Double-Blind Placebo-Controlled Trial of Combined Escitalopram and Memantine for Older Adults With Major Depression and Subjective Memory Complaints. Am J Geriatr Psychiatry. 2020;28(2):178-190.  https://doi.org/10.1016/j.jagp.2019.08.011
  24. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803-820.  https://doi.org/10.1007/s00401-016-1545-1

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register


We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.